Strengthening prevention programs to eliminate cervical cancer in the Nordic countries

References

• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–9
   PubMed Web of Science ®Google Scholar
• Engholm G, Storm HH, Ferlay J, Christensen N, Bray F, Olafsdottir E, , et al NORDCAN: Cancer Incidence and Mortality in the Nordic Countries, Version 3.0 Association of Nordic Cancer Registries, 2007. Danish Cancer Society ( http://www.ancr.nu)
   Google Scholar
• Bray F, Sankila R, Ferlay J, Parkin D. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002; 38: 99–166
   PubMed Web of Science ®Google Scholar
• Muir C, Parkin D. The world cancer burden: prevent or perish. Br Med J. 1985; 290: 5–6
   PubMedGoogle Scholar
• Munoz N, Bosch F, Sanjose SD, Herrero R, Castellsague X, Shah K, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518–27
   PubMed Web of Science ®Google Scholar
• Franceschi S, Clifford G. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97: 938–9
   PubMed Web of Science ®Google Scholar
• Solomon D, Schiffman M, Tarone R; ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomised trial. J Natl Cancer Inst. 2001;93:293–9.
   PubMed Web of Science ®Google Scholar
• Lorincz A, Richart R. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med. 2003; 127: 959–68
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Management of abnormal cervical cytology and histology. ACOG Practice Bulletin No. 66, September 2005. Obstet Gynecol. 2005;106:645–64.
   PubMedGoogle Scholar
• Davies P, Arbyn M, Dillner J, Kitchener H, Meijer C, Ronco G, et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer. 2006; 118: 791–6
   PubMed Web of Science ®Google Scholar
• Pagliusi S, Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004; 23: 569–78
   PubMed Web of Science ®Google Scholar
• Kjaer S, Hogdall F, Frederiksen K, Munk C, Brule Avd, Svare E, , et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66:10630–6.
   PubMed Web of Science ®Google Scholar
• Scott D, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, et al. Use of human papillomavirus DNA testing to compare equivocal cervical interpretations in the United States, Scandinavia, and the United Kingdom. Cancer. 2002; 96: 14–20
   PubMed Web of Science ®Google Scholar
• Forslund O, Antonsson A, Edlund K, Brule Avd, Hansson B, Meijer C, , et al Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol. 2002;66:535–41; Erratum in: J Med Virol. 2002;67:467.
   PubMed Web of Science ®Google Scholar
• Wahlström C, Iftner T, Dillner J, Dillner L. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol. 2007; 79: 1169–75
   PubMed Web of Science ®Google Scholar
• Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol. 1997; 36: 1–60
   PubMed Web of Science ®Google Scholar
• Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health. 2006; 6: 252
   PubMed Web of Science ®Google Scholar
• Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005; 93: 862–7
   PubMed Web of Science ®Google Scholar
• Roberts C, Tadesse A, Sands J, Halvorsen T, Schofield T, Dalen A, et al. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. J Clin Virol. 2006; 36: 277–82
   PubMed Web of Science ®Google Scholar
• Sigstad E, Lie A, Luostarinen T, Dillner J, Jellum E, Lehtinen M, et al. A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer. 2002; 87: 175–80
   PubMed Web of Science ®Google Scholar
• Sigurdsson K, Sigvaldason H. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. Eur J Cancer. 2007; 43: 769–74
   PubMed Web of Science ®Google Scholar
• Sigurdsson K, Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964–2002: a study on trends in incidence and mortality and the effect of risk factors. Acta Obstet Gynecol Scand. 2006; 85: 343–9
   PubMed Web of Science ®Google Scholar
• Sigurdsson K, Taddeo F, Benediktsdottir K, Olafsdottir K, Sigvaldason H, Oddsson K, et al. HPV genotypes in CIN 2–3 lesions and cervical cancer: a population-based study. Int J Cancer. 2007; 121: 2682–7
   PubMed Web of Science ®Google Scholar
• Clifford G, Smith J, Aguado T, Franceschi S. Comparison of HPV type distribution in high grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89: 101–5
   PubMed Web of Science ®Google Scholar
• Svare EI, Kjaer SK, Worm AM, Österlind A, Moi H, Christensen RB, et al. Risk factors for HPV infection in women from sexually transmitted disease clinics: comparison between two areas with different cervical cancer incidence. Int J Cancer. 1998; 75: 1–8
   PubMed Web of Science ®Google Scholar
• Nonnenmacher B, Krueger Kjaer S, Svare EI, Scott JD, Hubbert NL, van den Brule AJ, et al. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer in high-risk populations. Int J Cancer. 1996; 68: 704–9
   PubMed Web of Science ®Google Scholar
• Elfgren K, Rylander E, Rådberg T, Strander B, Strand A, Paajanen K, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol. 2005; 193: 650–7
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human Papillomavirus and papanicolaou tests to screen for cervical cancer. New Eng J Med. 2007; 357: 1589–97
   PubMed Web of Science ®Google Scholar
• Bistoletti P, Sennfält K, Dillner J. Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer. 2008; 122: 372–6
   PubMed Web of Science ®Google Scholar
• Arbyn M, Dillner J, Schenck U, Nieminen P, Weiderpass E, Silva DD, Chapter 3: Methods for screening and diagnosis. In: Arbyn M, et al, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, , et al. . European Guidelines of Quality Assurance in Cervical Cancer Screening. Luxembourg: European Commission, Office for Official Publications of the European Communities, 2008;69–152.
   Google Scholar
• Koutsky L, Harper D. Current findings from prophylactic HPV vaccine trials. Vaccine. 2006; 24: S114–21
   Web of Science ®Google Scholar
• Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine. 2006; 24: S233–41
   Web of Science ®Google Scholar
• Laukkanen P, Koskela P, Pukkala E, Dillner J, Läära E, Knekt P, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol. 2003; 84: 2105–9
   PubMed Web of Science ®Google Scholar
• French K, Barnabas R, Lehtinen M, Kontula O, Pukkala E, Dillner J, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer. 2007; 96: 514–8
   PubMed Web of Science ®Google Scholar